Barclays PLC Buys 10,116 Shares of Prothena Co. plc (NASDAQ:PRTA)

Barclays PLC raised its stake in Prothena Co. plc (NASDAQ:PRTA) by 10.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 105,338 shares of the biotechnology company’s stock after acquiring an additional 10,116 shares during the period. Barclays PLC owned approximately 0.20% of Prothena worth $1,458,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Headlands Technologies LLC lifted its position in shares of Prothena by 196.5% in the fourth quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company’s stock worth $102,000 after buying an additional 4,858 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in Prothena in the 4th quarter worth approximately $145,000. Purkiss Capital Advisors LLC purchased a new stake in shares of Prothena during the 4th quarter worth approximately $149,000. Chicago Partners Investment Group LLC bought a new position in shares of Prothena during the 4th quarter valued at approximately $159,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Prothena by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 1,065 shares in the last quarter. Hedge funds and other institutional investors own 97.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on PRTA. Chardan Capital reiterated a “buy” rating and set a $40.00 price objective on shares of Prothena in a research report on Friday, February 21st. Royal Bank of Canada lowered their price target on shares of Prothena from $24.00 to $20.00 and set a “sector perform” rating for the company in a report on Friday, February 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Prothena in a research note on Friday, February 21st. Piper Sandler raised their price objective on Prothena from $94.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Oppenheimer boosted their target price on Prothena from $58.00 to $62.00 and gave the company an “outperform” rating in a research report on Friday, February 7th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Prothena currently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Prothena Stock Performance

Shares of PRTA stock opened at $8.50 on Friday. The stock has a 50 day moving average price of $11.85 and a 200 day moving average price of $13.90. Prothena Co. plc has a 52-week low of $8.25 and a 52-week high of $25.42. The firm has a market capitalization of $457.53 million, a P/E ratio of -3.70 and a beta of 0.07.

Prothena (NASDAQ:PRTA) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.06). The business had revenue of $2.12 million for the quarter, compared to the consensus estimate of $7.53 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. As a group, sell-side analysts forecast that Prothena Co. plc will post -4.04 EPS for the current year.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.